611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Streptococcal Throat Infection Linked to Mental DisordersCognitive Decline Linked to Visual Field VariabilityRiboflavin Shows Positive Effect for Migraine in AdultsPromising Results for Drug to Fight Arthritis Linked to PsoriasisKidneys From Deceased Diabetics Might Ease Organ Shortage: StudyNew Cholesterol Fighting Meds Target Key GeneEye Problems May Be Tied to Zika, Lab Study SuggestsATS: Bronchial Thermoplasty Has Lasting Benefits for AsthmaSleepless Nights Could Pose Heart Risk DangersHospital Protocol Helps Thwart Serious InfectionZika Arrived in Florida at Least Four Different WaysKnow the Signs of Thyroid TroubleStudies Spotlight Diet, Supplements for Knee PainFunctional Interaction Seen for Dietary Carbohydrates With AMDTaking Opioids Before Knee Surgery Could Raise Pain LaterATS: First Abx Rx Doesn't Work for ~25% of Pneumonia CasesActemra Approved for Certain Blood Vessel InflammationStudy Casts Doubt on Need for Statins in the 'Healthy Old'First-Try Antibiotics Now Fail in 1 in 4 Adult Pneumonia CasesOvercrowded ERs Risky for Some Seriously Ill PatientsHigh Vitamin K1 Intake Linked to Reduced Cataract RiskPoverty Could Make Lupus Even WorseCDC: Crypto Outbreaks Linked to Pools Have Doubled Since 2014Could Cancer Drug Gleevec Help With Severe Asthma?Zika Mosquito Can Transmit Other Viruses, TooFDA OKs Kalydeco for Additional Mutations in Cystic FibrosisKalydeco Approval Widened for More Types of Cystic FibrosisAnother Step Toward Ebola ProtectionThe Water's Not Fine: U.S. Pool-Linked Infection Doubles in 2 YearsJust 2 Weeks on the Couch Can Trigger Body's DeclineGene Therapy Might Someday Mend Badly Broken Bones'Healthy Obese' May Be a MythNo Evidence Steroids Benefit Symptomatic Knee OsteoarthritisHeart Attack Risk Spikes After Respiratory Infection, Study FindsFor Inflamed Pancreas, Eating Right Away May Be Best MedicineFindings Support More Targeted Approach to Cholesterol ScreensHouston, You Have a 'Superbug'Forget Steroid Shots for Long-Term Relief of Arthritic KneesFDA Approves New Device to Treat Esophageal AtresiaMany U.S. Travelers Skip Measles Shots, Despite Infection RiskMany Under 40 May Not Need Regular Cholesterol Checks: StudyNew Device Approved for Esophageal Birth DefectACP: Recommendations Updated for Low Bone Density TreatmentMosquito-Borne Illnesses May Not Be Limited to TropicsArthroscopy for Degenerative Knees Deemed Seldom EffectiveBioengineered Intraabdominal Endocrine Pancreas FeasibleAllergies Getting Worse? Blame Climate ChangeA 2nd Life for Risky Kidney Transplants?Blood Vessel-Clearing Procedure Riskier on Weekends: StudyMultidrug-Resistant TB Set to Increase Through 2040
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Ischemic Outcomes Don't Vary With Gender in ACS Patients


HealthDay News
Updated: May 4th 2017

new article illustration

THURSDAY, May 4, 2017 (HealthDay News) -- For acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel, prasugrel, or ticagrelor, ischemic outcome does not differ by gender, according to a study published online April 29 in Cardiovascular Therapeutics.

Ioanna Xanthopoulou, M.D., from Patras University Hospital in Greece, and colleagues examined sex-based differences in ACS patients undergoing PCI and receiving clopidogrel, prasugrel, or ticagrelor. A total of 2,047 patients were recruited and followed for one year. The authors recorded major adverse cardiovascular events (MACE) and bleeding events (Bleeding Academic Research Consortium [BARC] classification).

The researchers found that clopidogrel was more frequently administered to women at PCI hospitalization and at discharge. MACE occurred in 9.2 percent of women and 8.1 percent of men, with no significant difference by gender. In women and men, the rate of observed bleeding of BARC any type was 57.2 and 44.4 percent, respectively. Differences in BARC any type and BARC type 1 events remained significant following adjustment, with higher rates seen for women (hazard ratios, 1.51 and 1.58, respectively; both P < 0.001)

"In a contemporary 'real life' cohort of ACS patients treated with PCI and focusing on antiplatelet treatment there are demographic, clinical, procedural, and treatment differences between sexes," the authors write. "One-year ischemic outcome does not differ by gender, while women do present more frequently [with] bleeding events."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)